|
Synonyms: SD-101 | SD101 | Zorblisa
Compound class:
Nucleic acid
Comment: Nelitolimod (SD-101) is a CpG oligonucleotide that is intended to act as a Toll-like receptor 9 (TLR9) agonist.
Full sequence is: all-P-ambo-P-thiothymidylyl-(3′→5′)-2'-deoxy-P-thiocytidylyl- (3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P- thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P- thiothymidylyl-(3′→5′)-P-thiothymidylyl-(3′→5′)-2'-deoxy-P- thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P- thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P- thiothymidylyl-(3′→5′)-P-thiothymidylyl-(3′→5′)-2'-deoxy-P- thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P- thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P- thiothymidylyl-(3′→5′)-P-thiothymidylyl-(3′→5′)-2'-deoxy-P- thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P- thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-thymidine |
| No information available. |
Summary of Clinical Use ![]() |
| Nelitolimod (SD-101) was initially progressed as a clinical candidate with anti-tumour potential [1]. It was later repurposed for potential to treat epidermolysis bullosa (EB). |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01042379 | I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 Interventional | QuantumLeap Healthcare Collaborative | ||
| NCT03007732 | Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT | Phase 2 Interventional | University of California, San Francisco | ||
| NCT07482787 | Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | Phase 3 Interventional | Paradigm Therapeutics | ||
| NCT07482813 | An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa | Phase 3 Interventional | Paradigm Therapeutics | ||